A5083283435- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Histone Deacetylase Inhibitors Research
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Neutropenia and Cancer Infections
- Hematological disorders and diagnostics
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Oral health in cancer treatment
- Immune Cell Function and Interaction
- Chemotherapy-related skin toxicity
- Biosimilars and Bioanalytical Methods
Case Western Reserve University
2016-2025
University Hospitals Seidman Cancer Center
2016-2025
University Hospitals Cleveland Medical Center
2015-2024
Case Comprehensive Cancer Center
2020-2024
University Hospitals of Cleveland
2017-2023
Universität Hamburg
2023
University Medical Center Hamburg-Eppendorf
2023
Norfolk and Norwich University Hospitals NHS Foundation Trust
2023
Mayo Clinic in Florida
2023
University School
2016-2023
The NCCN Guidelines for Multiple Myeloma provide recommendations diagnosis, evaluation, treatment, including supportive-care, and follow-up patients with myeloma. These Insights highlight the important updates/changes specific to myeloma therapy options in 2018 version of Guidelines.
The NCCN Guidelines for Multiple Myeloma provide recommendations diagnosis, workup, treatment, follow-up, and supportive care patients with monoclonal gammopathy of renal significance, solitary plasmacytoma, smoldering myeloma, multiple myeloma. These Insights highlight some the important updates changes in 1.2020 version Myeloma.
Although the therapeutic benefit of proteasome inhibition in multiple myeloma remains unchallenged, drug resistance inevitably emerges through mechanisms that remain elusive. Bortezomib provokes unwanted protein accumulation and endoplasmic reticulum stress to activate unfolded response (UPR) autophagy as compensatory restore homeostasis. High-throughput screens detect pharmacologics modulated enhance anti-myeloma effect bortezomib revealed metformin, a widely used antidiabetic agent with...
The curative potential of allogeneic hematopoietic transplantation (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) is hampered by relapse. Inotuzumab ozogamicin (INO) an anti-CD22 monoclonal antibody bound to calicheamicin, which has significant activity against ALL. We hypothesized that low-dose INO would be safe and feasible after allo-HCT. Therefore, we conducted a phase 1 study determine the dose safety this setting. Patients were eligible if they aged 16 75 years, had...
// Mohamed A.Y. Abdel Malek 1,2,3,* , Sajjeev Jagannathan 1,2,* Ehsan 1,2 Douaa M. Sayed 4 Sahar A. Elgammal 3 Hanan G. Abd El-Azeem Nabila Thabet and James J. Driscoll 1,2,5,6 1 The Vontz Center for Molecular Studies, University of Cincinnati College Medicine, Cincinnati, OH 2 Division Hematology Oncology, Department Clinical Pathology, Faculty Assiut University, Assiut, Egypt South Cancer Institute, 5 Biology, 6 * These authors contributed equally to this work Correspondence: Driscoll,...
Background Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease older adults. Methods The authors investigated outcomes AHCT MM who were aged ≥70 years. Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 United States within 12 months diagnosis during 2013 through 2017; total 2092 Nonrecurrence mortality (NRM), recurrence and/or...
While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2 (SCFSkp2) promotes proteasomal degradation cell cycle p27 to enhance tumor growth. Increased SKP2 expression reduced levels are frequent in human cancers associated with therapeutic resistance. SCFSkp2 activity is increased by Cullin-1-binding protein...
Abstract Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma–reactive lymphocytes and consolidation clinical response following autologous hematopoietic transplant (auto-HCT). Patients Methods: In this randomized phase II trial (NCT02728102), we assessed effect DC/MM fusion vaccination, GM-CSF, lenalidomide maintenance as compared control arms GM-CSF or alone on rates induction myeloma–specific...
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves efficacy cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov., NCT03143985) to determine primary endpoints safety, tolerability, maximal tolerated dose (200 mg twice daily) for orally-available TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide relapsed and/or refractory multiple myeloma (RRMM) patients who had received ≥2 lines...
Summary Patients with relapsed/refractory multiple myeloma (RRMM) for whom the benefits of lenalidomide have been exhausted in early treatment lines need effective therapies. In cohort A phase 2 MM‐014 trial, we examined safety and efficacy pomalidomide plus low‐dose dexamethasone immediately after lenalidomide‐based failure patients RRMM two prior therapy. Pomalidomide 4 mg was given on days 1 to 21 28‐day cycles. Dexamethasone 40 (20 aged >75 years) 1, 8, 15 22 The primary endpoint...